Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Credit Suisse 31st Annual Healthcare Conference
A virtual presentation will be made live starting on Tuesday, November 8, 2022
Stifel 2022 Healthcare Conference
Fireside chat: Wednesday, November 16, 2022 at 10:20 am EST
Location: Lotte New York Palace Hotel, New York, NY
Jefferies London Healthcare Conference
Fireside chat: Thursday, November 17, 2022 at 3:15 pm GMT (10:15 am EST)
Location: The Waldorf Hilton, London, UK
A live webcast and archived replay of the fireside chats along with a replay of the pre-recorded presentation will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
